Cantor Fitzgerald’s Novo Nordisk NVO Stock Holding History

Cantor Fitzgerald’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.61M	Sell	261,574 -314,653	-55%	-$14.9M	0.14%	74
2025 Q4	$29.3M	Sell	576,227 -280,773	-33%	-$14.4M	0.44%	54
2025 Q3	$47.6M	Buy	857,000 +801,777	+1,452%	+$46.9M	0.46%	45
2025 Q2	$3.81M	Buy	55,223 +17,993	+48%	+$1.22M	0.07%	72
2025 Q1	$2.59M	Buy	37,230 +2,157	+6%	+$178K	0.05%	71
2024 Q4	$3.02M	Buy	+35,073	New	+$3.79M	0.06%	49
2024 Q3	–	Sell	-5,100	Closed	-$728K	–	282
2024 Q2	$728K	Sell	5,100 -2,696	-35%	-$357K	0.14%	89
2024 Q1	$1M	Buy	+7,796	New	+$928K	0.24%	61
2023 Q4	–	Sell	-3,971	Closed	-$361K	–	456
2023 Q3	$361K	Buy	+3,971	New	+$350K	0.01%	361
2023 Q1	–	Sell	-6,400	Closed	-$433K	–	712
2022 Q4	$433K	Buy	+6,400	New	+$375K	0.01%	480

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Cantor Fitzgerald's NVO Position: Q1 2026 in Review

Cantor Fitzgerald reduced its Novo Nordisk (NVO) stake by 55% in Q1 2026, selling an estimated $14.9M and leaving 261,574 shares worth $9.61M. The position accounts for 0.14% of the portfolio, ranked #74.

Cantor Fitzgerald first reported a position in NVO in Q4 2022 and has held it in 10 quarters since. The position peaked at $47.6M in Q3 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Cantor Fitzgerald held 261,574 shares of Novo Nordisk worth $9.61M as of Q1 2026.
Cantor Fitzgerald sold 314,653 Novo Nordisk shares in Q1 2026, an estimated $14.9M.
Novo Nordisk made up 0.14% of Cantor Fitzgerald's portfolio in Q1 2026, its #74 holding.
Cantor Fitzgerald first reported a position in Novo Nordisk in Q4 2022 and has held it in 10 quarters since.
Cantor Fitzgerald's Novo Nordisk position peaked at $47.6M in Q3 2025.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.